Mathias Schmidt, Ph.D.›
President and Chief Executive Officer
Dr. Schmidt joined ArmaGen as the president and chief executive officer, as well as member of ArmaGen’s board of directors, in October 2016. Dr. Schmidt has more than 17 years of global biopharmaceutical industry experience in executive management focused on the research and development of biotherapeutics and pharmaceuticals. Prior to ArmaGen, he held various positions with Takeda Pharmaceuticals and its subsidiaries since 2001, including oncology drug discovery, early alliance management and overseeing biologics. He joined Takeda California in 2012 as Vice President of Biological Sciences where he built a highly functional Biotherapeutics unit serving all therapeutic indications and all research sites within the global Takeda organization. In 2011, he was awarded the venia legendi in pharmacology from the University of Konstanz. He and his team developed a HER-2 specific immunotoxin that subsequently entered the clinic when he studied at the University of Freiburg. After working for several years at various cancer hospitals in Germany and the U.S., he joined the pharmaceutical industry in 1999, where he developed a great passion for drug discovery and development, especially for protein therapeutics.
He holds an M.S. degree in Biotechnology from the University of Stuttgart (Germany) and a Ph.D. in Tumor Biology (summa cum laude) from the University of Freiburg. He studied cellular biology and pharmacology at the University of Constance.
Stuart J. Swiedler, M.D., Ph.D.›
Dr. Swiedler is a biotechnology consultant with more than 20 years of experience in the biotechnology field, primarily as a scientist and junior executive at Glycomed, Inc., and as a clinical scientist and senior executive at BioMarin Pharmaceutical, Inc. Over a 10-year period at BioMarin, he contributed to both the non-clinical and clinical aspects of drug development for the regulatory approvals of the orphan drugs Aldurazyme, Naglazyme and Kuvan. He continues to focus on orphan drug products for genetic diseases, working with both biotech companies and investment firms. He received his Bachelor of Science degree from the University at Albany, and his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine. He completed a residency program in Anatomic Pathology at Yale University School of Medicine and Duke University School of Medicine, and a post-doctoral fellowship at Duke.
William M. Pardridge, M.D.›
Founder and Chief Scientific Officer
Dr. Pardridge formed ArmaGen in 2003 and supported the company the first 10 years with $20 million in non-dilutive funding. Dr. Pardridge, who is a Distinguished Professor Emeritus, UCLA, is a recognized leader in blood brain barrier (BBB) research. He has focused on the area since 1970, and is credited with inventing antibody directed receptor-mediated transcytosis technology, the liposome technology for non-viral, non-invasive gene therapy of the brain, and the field of BBB genomics. He is the author of over 500 publications, more than 450 of which focus on the BBB. Dr. Pardridge is board certified in Internal Medicine, and Endocrinology and Metabolism.
Martin Heidecker, Ph.D.›
Boehringer Ingelheim Venture Fund (BIVF)
Dr. Heidecker has 15 years of investment and commercial experience with venture capital and global pharmaceutical companies. He established the U.S.-office of Boehringer Ingelheim Venture Fund (BIVF) where he is focusing on biotech seed-investments. He previously held Senior Business Analyst and Director roles within the Global Business Analysis department, providing strategic marketing support for CNS, Women’s Health and Oncology. Prior to joining Boehringer Ingelheim (BI), Martin held several positions within the global Business Intelligence Department of Solvay Pharmaceuticals, focusing primarily on compounds in early clinical stages. Before Solvay, Martin was an investment manager at Bayern Kapital. During this time, he led co-investments in early stage drug development, medical devices, and bioinformatic companies. Dr. Heidecker holds a Ph.D. in Biology, focusing on membrane transport proteins in his thesis. He also has a Master’s degree in Biology and Economics.
Michael Martin, Ph.D.›
Head of Takeda Ventures, Inc.
Dr. Michael Martin is the Global Head of Takeda Ventures, Inc. (TVI), and he is based in San Diego, CA. His professional background includes venture capital, pharma business development and broad R&D experiences with an integral role in the discovery and preclinical/clinical development of 17 innovative investigational drugs and 2 commercial products. Prior to joining TVI, Dr. Martin was most recently a member of Global Licensing and Business Development at Takeda, heading efforts for sourcing and transacting technologies and early stage pipeline programs. Dr. Martin joined Takeda in January 2012 through the acquisition of Intellikine where he was Vice President of Preclinical Development. Additionally, he has held executive and senior management and scientific positions with TargeGen (acquired by Sanofi-Aventis), Arena Pharmaceuticals, and Monsanto Corporation. Dr. Martin earned his doctorate in Medicinal Chemistry from the University of Illinois and holds a M.S. degree in analytical chemistry and B.S. degrees in Chemistry and Mathematics.
Masaji Matsuoka (Observer)›
Senior Associate, Mitsui Global Investment
Mr. Matsuoka is a Director in the Investment Division of Mitsui Global Investment. He previously worked in the Principal Investment Division at Mitsui & Co. Ltd, where he was involved with various investment transactions within the healthcare and industrial sectors. Prior to that, he was in the Asset Management Division at Mitsui & Co., focusing on the alternative fund business and fund raising. He started his career at Mitsui in 2004. He holds a Bachelor of Law from the University of Tokyo.